Document Detail


Lipid response to pioglitazone in diabetic patients: clinical observations from a retrospective chart review.
MedLine Citation:
PMID:  12079617     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The objective of this study was to determine whether improvements in the lipid profile observed in controlled clinical trials with pioglitazone are seen in the clinical practice setting, and to ascertain the influence of concurrent statin treatment. Charts of 100 consecutive patients with type 2 diabetes (mean age 56.8 years) treated with pioglitazone (45 mg/day) for 2-4 months were retrospectively analyzed for changes in serum lipids, glycemic parameters, and body weight. Subanalyses were performed on the relationship of lipid changes to baseline lipid values and to concurrent statin therapy. Pioglitazone was associated with statistically significant (p < 0.001) changes from baseline in HbA(1C) (mean decrease 1.09%), body weight (mean increase 1.76 kg), HDL cholesterol (HDL-C) levels (mean increase 15.6%), and triglycerides (mean decrease 9.9%). There was an increase (+ 1.09%) in mean individual LDL-C levels from baseline values, but this change was not statistically significant. The greatest absolute and percentage improvements in HDL-C and triglycerides were observed in patients who had the greatest lipid abnormalities at baseline: in patients with baseline HDL-C < 35 mg/dL, mean individual HDL-C values increased by 31% (p < 0.001); in those with baseline triglycerides >399 mg/dL, triglyceride levels decreased by 46% (p < 0.001); and in patients with baseline LDL-C > 129 mg/dL, mean individual LDL-C values decreased by 10.6% (p < 0.001). Subgroup analysis showed similar beneficial changes in HDL-C and triglycerides in patients who were not receiving concurrent statin therapy (n = 48) as in those who were receiving statins (n = 49). This observational study demonstrated that significant improvements in HDL-C and triglyceride levels can be achieved with pioglitazone in the clinical practice setting. The greatest improvements occurred in patients with the worst baseline lipid levels, and benefits were seen regardless of whether patients were receiving concurrent statin therapy.
Authors:
Allen B King; Dana U Armstrong
Related Documents :
12727577 - A randomized trial of aggressive lipid reduction for improvement of myocardial ischemia...
19747737 - Plasma levels of lipoprotein (a) in patients with major depressive disorders.
12702127 - Trizal study: switching from successful haart to trizivir (abacavir-lamivudine-zidovudi...
12880147 - Association between increased serum cholesterol and signs of depressive mood.
22223607 - Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis.
12446187 - Short-term consumption of probiotic-containing cheese and its effect on dental caries r...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Diabetes technology & therapeutics     Volume:  4     ISSN:  1520-9156     ISO Abbreviation:  Diabetes Technol. Ther.     Publication Date:  2002  
Date Detail:
Created Date:  2002-06-24     Completed Date:  2002-12-04     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  100889084     Medline TA:  Diabetes Technol Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  145-51     Citation Subset:  IM    
Affiliation:
Diabetes Care Center, 1119 Pajaro Street, Salinas, CA 93901, USA. akvineyards@email.msn.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anticholesteremic Agents / therapeutic use
Blood Glucose / metabolism
Body Weight / drug effects
California
Cholesterol, HDL / blood
Cholesterol, LDL / blood
Diabetes Mellitus, Type 2 / blood,  drug therapy*
Drug Therapy, Combination
Ethnic Groups
Female
Hemoglobin A, Glycosylated / metabolism
Humans
Hypoglycemic Agents / therapeutic use*
Lipids / blood*
Male
Middle Aged
Retrospective Studies
Thiazoles / therapeutic use*
Thiazolidinediones*
Triglycerides / blood
Chemical
Reg. No./Substance:
0/Anticholesteremic Agents; 0/Blood Glucose; 0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Hemoglobin A, Glycosylated; 0/Hypoglycemic Agents; 0/Lipids; 0/Thiazoles; 0/Thiazolidinediones; 0/Triglycerides; 111025-46-8/pioglitazone
Comments/Corrections
Comment In:
Diabetes Technol Ther. 2002;4(2):153-5   [PMID:  12079618 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Oxidative DNA damage in male Wistar rats exposed to di-n-butyl phthalate.
Next Document:  Inhaled insulin and insulin antibodies: a new twist to an old debate.